NASDAQ:CBAY - CymaBay Therapeutics Stock Price, Forecast & News

$1.95

-0.07 (-3.47 %)

(As of 01/22/2020 06:00 AM ET)

Add

Compare

Today's Range

$1.95

Now: $1.95▼

$2.11

50-Day Range

$1.65

MA: $1.89▼

$2.06

52-Week Range

$1.29

Now: $1.95▼

$14.00

Volume1.50 million shs

Average Volume857,384 shs

Market Capitalization$133.97 million

P/E RatioN/A

Dividend YieldN/A

Beta1.13

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CBAY

Previous Symbol

CUSIPN/A

CIK1042074

Webhttp://www.cymabay.com/

Phone510-293-8800

Debt

Debt-to-Equity Ratio0.01

Current Ratio13.12

Quick Ratio13.12

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$10 million

Price / Sales13.40

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.87 per share

Price / Book0.68

Profitability

EPS (Most Recent Fiscal Year)($1.26)

Net Income$-72,550,000.00

Net MarginsN/A

Return on Equity-42.36%

Return on Assets-39.25%

Miscellaneous

Employees43

Outstanding Shares68,700,000

Market Cap$133.97 million

Next Earnings Date2/27/2020 (Estimated)

OptionableOptionable

Receive CBAY News and Ratings via Email

Sign-up to receive the latest news and ratings for CBAY and its competitors with MarketBeat's FREE daily newsletter.

(Ad)

Each week, an exclusive group of investors receives access to a simple list of 3 stocks to put on their radar for the week ahead.

You can sign up today to receive access to next week's watchlist -- generated by a proprietary methodology -- at no cost or obligation.

CymaBay Therapeutics (NASDAQ:CBAY) Frequently Asked Questions

What is CymaBay Therapeutics' stock symbol?

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics Inc (NASDAQ:CBAY) released its quarterly earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.37) by $0.01. View CymaBay Therapeutics' Earnings History.

When is CymaBay Therapeutics' next earnings date?

CymaBay Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for CymaBay Therapeutics.

What price target have analysts set for CBAY?

13 brokers have issued twelve-month price targets for CymaBay Therapeutics' stock. Their forecasts range from $2.00 to $18.00. On average, they expect CymaBay Therapeutics' share price to reach $6.95 in the next twelve months. This suggests a possible upside of 256.6% from the stock's current price. View Analyst Price Targets for CymaBay Therapeutics.

What is the consensus analysts' recommendation for CymaBay Therapeutics?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last year. There are currently 10 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for CymaBay Therapeutics.

What are Wall Street analysts saying about CymaBay Therapeutics stock?

Here are some recent quotes from research analysts about CymaBay Therapeutics stock:

1. According to Zacks Investment Research, "CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California. " (1/7/2020)
2. HC Wainwright analysts commented, "916-3963, Rating POS Risk-adj value Full value Shares outstanding 68,696 S/O as of April 30, 2019. Current share price $6.05 Discount rate 20.0% Seladelpar (PBC) – U.S." (6/12/2019)
3. Cantor Fitzgerald analysts commented, ". Reiterate our Overweight rating; increasing 12-mo. PT to $20. CymaBay is a liver disease company with lead asset, seladelpar, in Ph3 for primary biliary cholangitis (PBC). Our checks suggest seladelpar’s strong profile in PBC has the potential to grow the market significantly from where it is today. We think the opportunity in PBC alone (~$350M in 2026 unadjusted sales vs. cap of $500M) should justify upside. We see further potential for seladelpar with a 2Q19 Ph2b NASH proof of concept readout, which could be a much larger opportunity (~ $4B+) for Seladelpar if successful. In our 75-page slide deck, we took a close look at PPAR-delta biology & role in NASH. Our Take: PPAR-delta has the potential to be a major target in the NASH space." (2/1/2019)

Has CymaBay Therapeutics been receiving favorable news coverage?

Media headlines about CBAY stock have trended somewhat negative on Wednesday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. CymaBay Therapeutics earned a news sentiment score of -1.5 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for CymaBay Therapeutics.

Are investors shorting CymaBay Therapeutics?

CymaBay Therapeutics saw a increase in short interest in the month of December. As of December 13th, there was short interest totalling 7,160,000 shares, an increase of 5.3% from the November 28th total of 6,800,000 shares. Based on an average daily volume of 2,070,000 shares, the short-interest ratio is currently 3.5 days. Approximately 11.7% of the company's shares are sold short. View CymaBay Therapeutics' Current Options Chain.

Who are some of CymaBay Therapeutics' key competitors?

Some companies that are related to CymaBay Therapeutics include MacroGenics (MGNX), Magenta Therapeutics (MGTA), Neoleukin Therapeutics (NLTX), Clovis Oncology (CLVS), BioDelivery Sciences International (BDSI), Viking Therapeutics (VKTX), Molecular Templates (MTEM), OrganiGram (OGI), Dynavax Technologies (DVAX), Milestone Pharmaceuticals (MIST), DURECT (DRRX), Rigel Pharmaceuticals (RIGL), Ardelyx (ARDX), Arcus Biosciences (RCUS) and Organogenesis (ORGO).

What other stocks do shareholders of CymaBay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Exelixis (EXEL), Energy Transfer LP Unit (ET), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Alibaba Group (BABA), Abeona Therapeutics (ABEO), Corbus Pharmaceuticals (CRBP), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE) and TherapeuticsMD (TXMD).

Who are CymaBay Therapeutics' key executives?

CymaBay Therapeutics' management team includes the folowing people:

Mr. Sujal A. Shah, Pres, CEO & Director (Age 46)
Mr. Daniel Menold, VP of Fin. (Age 49)
Dr. Charles A. McWherter, Sr. VP & Chief Scientific Officer (Age 64)
Mr. Paul T. Quinlan, Gen. Counsel & Corp. Sec. (Age 56)
Dr. Pol F. Boudes, Chief Medical Officer (Age 62)

Who are CymaBay Therapeutics' major shareholders?

CymaBay Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Diversified Trust Co (0.03%). Company insiders that own CymaBay Therapeutics stock include Carl Goldfischer, Daniel Menold, Kurt Von Emster and Sujal Shah. View Institutional Ownership Trends for CymaBay Therapeutics.

Which institutional investors are buying CymaBay Therapeutics stock?

CBAY stock was bought by a variety of institutional investors in the last quarter, including Diversified Trust Co. View Insider Buying and Selling for CymaBay Therapeutics.

How do I buy shares of CymaBay Therapeutics?

Shares of CBAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is CymaBay Therapeutics' stock price today?

One share of CBAY stock can currently be purchased for approximately $1.95.

How big of a company is CymaBay Therapeutics?

CymaBay Therapeutics has a market capitalization of $133.97 million and generates $10 million in revenue each year. The biopharmaceutical company earns $-72,550,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. CymaBay Therapeutics employs 43 workers across the globe.View Additional Information About CymaBay Therapeutics.

What is CymaBay Therapeutics' official website?

The official website for CymaBay Therapeutics is http://www.cymabay.com/.

How can I contact CymaBay Therapeutics?

CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-293-8800 or via email at [email protected]

MarketBeat Community Rating for CymaBay Therapeutics (NASDAQ CBAY)

Community Ranking:		2.9 out of 5 ( )
Outperform Votes:		402 (Vote Outperform)
Underperform Votes:		282 (Vote Underperform)
Total Votes:		684

MarketBeat's community ratings are surveys of what our community members think about CymaBay Therapeutics and other stocks. Vote "Outperform" if you believe CBAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBAY will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 1/22/2020 by MarketBeat.com Staff

Your Ultimate Investing Toolkit

Just $1.00 for your first month.